Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GPhA Waxman/Hatch Plan Would Use Bonds To Protect 180-Day Exclusivity

Executive Summary

The Generic Pharmaceutical Association is proposing to change the Waxman/Hatch patent challenge process to use bonds posted by brand name companies as a substitute for market exclusivity to provide an incentive for generic companies.

You may also be interested in...



McCain/Schumer Generic Bill Would End 30-Month Stay Of Approval

The revised McCain/Schumer generic drug bill eliminates the automatic stay of approval under current patent challenge procedures.

McCain/Schumer Generic Bill Would End 30-Month Stay Of Approval

The revised McCain/Schumer generic drug bill eliminates the automatic stay of approval under current patent challenge procedures.

FTC K-Dur Suit Would Allow Andrx Generic Launch; FDA Could Act First

Andrx believes it may be able to launch a generic version of Schering-Plough's K-Dur during the second half of the year regardless of the outcome of the Federal Trade Commission's administrative action over patent settlements involving K-Dur.

Related Content

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel